Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Frequent Social Media Use Harmful for High School Students
TUESDAY, Oct. 8, 2024 -- Frequent social media use is potentially harmful for adolescent mental health among U.S. high school students, according to research...
Socioeconomic Factors Tied to Sickle Cell Complications in Preschoolers
TUESDAY, Oct. 8, 2024 -- For preschool-aged children with sickle cell disease (SCD), social determinants of health (SDOH) are associated with the risk for...
American Society for Radiation Oncology, Sept. 29-Oct. 2
The annual meeting of the American Society for Radiation Oncology was held from Sept. 29 to Oct. 2 in Washington, D.C., drawing more than 8,500 participants...
3% of U.S. High School Students Identify as Transgender, First National Survey Finds
WEDNESDAY, Oct. 9, 2024 (HealthDay news) -- About 3% of U.S. high school students identify as transgender, according to the first federal attempt to gather...
Social Risk Factors Tied to Lower Odds of Receiving Preventive Services
TUESDAY, Oct. 8, 2024 -- Social risk factors are associated with decreased odds of receiving preventive services such as mammograms, Papanicolaou (Pap) tests...
AI May Identify Women at Risk for Future Breast Cancer
TUESDAY, Oct. 8, 2024 -- Artificial intelligence (AI) scores may be able to estimate the risk for future breast cancer and lead to earlier diagnosis, according...
EPA Finalizes Rule to Require Removal of Lead Pipes in U.S. Water System
TUESDAY, Oct. 8, 2024 -- The U.S. Environmental Protection Agency on Tuesday finalized a rule that will require the removal of all lead pipes from the...
CDC Will Test Travelers From Rwanda for Ebola-Like Marburg Virus
TUESDAY, Oct. 8, 2024 -- As health officials work furiously to stem the spread of Marburg virus in Rwanda, U.S. health officials announced Monday that all...
Breast Cancer Treatments Might Speed Aging, Study Finds
TUESDAY, Oct. 8, 2024 -- Any form of breast cancer treatment appears to speed the aging of the recipient's cells, a new study finds. “For the first...
Could Music Lessons Help Clear the 'Brain Fog' of Chemotherapy?
TUESDAY, Oct. 8, 2024 -- In a small, preliminary study, piano lessons provided to cancer patients undergoing chemotherapy appeared to help them maintain brain...
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Oct. 3, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and...
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.J.--(BUSINESS WIRE) Oct 03, 2024 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved...
FDA Approves Otulfi (ustekinumab-aauz), a Biosimilar to Stelara
September 30, 2024 -- Fresenius Kabi, an operating company of Fresenius, specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V...
Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients with COPD
Paris and Tarrytown, NY, September 27, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of...
FDA Approves Flyrcado (flurpiridaz F 18) Radioactive Diagnostic for Enhanced Diagnosis of Coronary Artery Disease
ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE) September 27, 2024 --GE HealthCare (Nasdaq: GEHC) today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Cobenfy (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
PRINCETON, N.J.--(BUSINESS WIRE)--26 September 2024-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has...
Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Boosted by CARES-310 Leading Overall Survival Analysis
FORT LEE, NEW JERSEY, Sept. 23, 2024 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today announced the resubmission of a New...
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development...
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies...
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S. Food...
First Patients Dosed in Phase 1a/b Clinical Trial of RGT-61159, an Oral Small Molecule Targeting MYB, in Adenoid Cystic Carcinoma and Colorectal Cancer
WOBURN, Mass., Oct. 8, 2024. Rgenta Therapeutics, a biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and...
First Patient Dosed in Clinical Study of PT886 in Combination with Keytruda
SAN DIEGO, Oct. 8, 2024. Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology...
TCI Unveils Promising GLP-1 Formula Clinical Trial Results for Advanced Weight Management
TAIPEI, Oct. 7, 2024. TCI Co., Ltd. ("TCI"), a global CDMO leader in health and skincare solutions, is pleased to announce the successful results of its recent...
First Healthy Volunteer Dosed with HT-4253, a Novel Oral LRRK2 Inhibitor Targeting Neuroinflammation in Alzheimer's Disease
LEHI, Utah, Oct. 7, 2024. Halia Therapeutics, a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for inflammatory...
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
NEW HAVEN, Conn., Oct. 3, 2024. Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.